Cargando…
Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
OBJECTIVE: To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. RESEARCH DESIGN AND METHODS: Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-we...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241299/ https://www.ncbi.nlm.nih.gov/pubmed/22040840 http://dx.doi.org/10.2337/dc11-0931 |
_version_ | 1782219502718550016 |
---|---|
author | Dushay, Jody Gao, Chuanyun Gopalakrishnan, Gosala S. Crawley, Meghan Mitten, Emilie K. Wilker, Elissa Mullington, Janet Maratos-Flier, Eleftheria |
author_facet | Dushay, Jody Gao, Chuanyun Gopalakrishnan, Gosala S. Crawley, Meghan Mitten, Emilie K. Wilker, Elissa Mullington, Janet Maratos-Flier, Eleftheria |
author_sort | Dushay, Jody |
collection | PubMed |
description | OBJECTIVE: To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. RESEARCH DESIGN AND METHODS: Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention. The primary outcome was change in body weight. RESULTS: Subjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment. Weight loss with exenatide treatment was noted at 2 weeks. The degree of weight loss could be stratified. A total of 30% of subjects were high responders who lost ≥5% body weight (−7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (−2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%). Waist circumference also decreased significantly with exenatide treatment. Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss. CONCLUSIONS: Short-term exenatide treatment was associated with modest weight loss and decreased waist circumference in a cohort of obese nondiabetic women. A subset of individuals demonstrated robust weight loss that was detected very early in the course of treatment. |
format | Online Article Text |
id | pubmed-3241299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-32412992013-01-01 Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes Dushay, Jody Gao, Chuanyun Gopalakrishnan, Gosala S. Crawley, Meghan Mitten, Emilie K. Wilker, Elissa Mullington, Janet Maratos-Flier, Eleftheria Diabetes Care Original Research OBJECTIVE: To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. RESEARCH DESIGN AND METHODS: Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention. The primary outcome was change in body weight. RESULTS: Subjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment. Weight loss with exenatide treatment was noted at 2 weeks. The degree of weight loss could be stratified. A total of 30% of subjects were high responders who lost ≥5% body weight (−7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (−2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%). Waist circumference also decreased significantly with exenatide treatment. Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss. CONCLUSIONS: Short-term exenatide treatment was associated with modest weight loss and decreased waist circumference in a cohort of obese nondiabetic women. A subset of individuals demonstrated robust weight loss that was detected very early in the course of treatment. American Diabetes Association 2012-01 2011-12-09 /pmc/articles/PMC3241299/ /pubmed/22040840 http://dx.doi.org/10.2337/dc11-0931 Text en © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Original Research Dushay, Jody Gao, Chuanyun Gopalakrishnan, Gosala S. Crawley, Meghan Mitten, Emilie K. Wilker, Elissa Mullington, Janet Maratos-Flier, Eleftheria Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes |
title | Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes |
title_full | Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes |
title_fullStr | Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes |
title_full_unstemmed | Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes |
title_short | Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes |
title_sort | short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241299/ https://www.ncbi.nlm.nih.gov/pubmed/22040840 http://dx.doi.org/10.2337/dc11-0931 |
work_keys_str_mv | AT dushayjody shorttermexenatidetreatmentleadstosignificantweightlossinasubsetofobesewomenwithoutdiabetes AT gaochuanyun shorttermexenatidetreatmentleadstosignificantweightlossinasubsetofobesewomenwithoutdiabetes AT gopalakrishnangosalas shorttermexenatidetreatmentleadstosignificantweightlossinasubsetofobesewomenwithoutdiabetes AT crawleymeghan shorttermexenatidetreatmentleadstosignificantweightlossinasubsetofobesewomenwithoutdiabetes AT mittenemiliek shorttermexenatidetreatmentleadstosignificantweightlossinasubsetofobesewomenwithoutdiabetes AT wilkerelissa shorttermexenatidetreatmentleadstosignificantweightlossinasubsetofobesewomenwithoutdiabetes AT mullingtonjanet shorttermexenatidetreatmentleadstosignificantweightlossinasubsetofobesewomenwithoutdiabetes AT maratosfliereleftheria shorttermexenatidetreatmentleadstosignificantweightlossinasubsetofobesewomenwithoutdiabetes |